PIBF1 and IL-33 Proteins for Preterm Labor Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Preterm labor remains a significant cause of neonatal mortality and long-term morbidity, with existing methods failing to effectively prevent or inhibit it.

Innovation Solution

Administration of therapeutically effective amounts of PIBF1, IL-33, or their variants to pregnant subjects, either as proteins or encoded by expression vectors, to prevent and inhibit preterm labor by suppressing uterine inflammation and neutrophil activation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing prevention methods are used, then preterm labor can be addressed, but they fail to effectively prevent or inhibit it

Engineering Contradiction:

Improveeffectiveness of preterm labor preventionVSAvoidcomplexity of treatment protocol

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces PIBF1 and IL-33 as intermediary substances that mediate between the inflammatory response and uterine contraction. These proteins act as biological mediators that specifically target the inflammatory pathway leading to preterm labor, providing a more effective and targeted intervention compared to existing broad-spectrum approaches.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the biochemical parameters of the system by introducing specific proteins (PIBF1 and IL-33) that alter the inflammatory response parameters. This involves changing the molecular composition and signaling pathways in the uterus, transforming the physiological state from inflammatory to protective, thereby preventing preterm labor effectively.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If PIBF1 or IL-33 is administered to suppress uterine inflammation, then preterm labor is prevented, but the mechanism of action requires precise biological targeting

Engineering Contradiction:

Improvepreterm labor inhibition efficacyVSAvoidmeasurement of inflammatory suppression

Core Design Contradiction:

ReliabilityVSDifficulty of detecting and measuring

Solution Approach 1:

The patent employs feedback mechanisms where PIBF1 and IL-33 administration is guided by and adjusted according to measured inflammatory markers and clinical response. This feedback loop allows for optimization of treatment dosage and timing, ensuring effective suppression of uterine inflammation while monitoring the biological response to maintain reliability.

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS10391148B2Method of prevention and inhibition of preterm labor

Publication Date: 2019.08.27 WAYNE STATE UNIV

AI summary

Methods for preventing and/or inhibiting preterm labor in a pregnant subject, such as a human subject, are disclosed according to the invention including administering a therapeutically effective amount of a protein selected from the group consisting of: PIBF1, a fragment or variant thereof; IL-33, a fragment or variant thereof; and a combination of any two or more thereof. Pharmaceutical compositions for preventing and/or inhibiting preterm labor in a pregnant subject, such as a human subject, are disclosed according to the invention including a therapeutically effective amount of a protein selected from the group consisting of: PIBF1, a fragment or variant thereof; IL-33, a fragment or variant thereof; and a combination of any two or more thereof.